120 related articles for article (PubMed ID: 9682276)
1. Glutamatergic compensatory mechanisms in experimental parkinsonism.
Bezard E; Bioulac B; Gross CE
Prog Neuropsychopharmacol Biol Psychiatry; 1998 May; 22(4):609-23. PubMed ID: 9682276
[TBL] [Abstract][Full Text] [Related]
2. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P
Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
[TBL] [Abstract][Full Text] [Related]
3. Presymptomatic revelation of experimental parkinsonism.
Bezard E; Boraud T; Bioulac B; Gross CE
Neuroreport; 1997 Jan; 8(2):435-8. PubMed ID: 9080424
[TBL] [Abstract][Full Text] [Related]
4. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
Neurosci Lett; 1986 Jan; 63(1):61-5. PubMed ID: 3485267
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms.
Bezard E; Boraud T; Bioulac B; Gross CE
Eur J Neurosci; 1999 Jun; 11(6):2167-70. PubMed ID: 10336685
[TBL] [Abstract][Full Text] [Related]
6. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism.
Bezard E; Boraud T; Bioulac B; Gross CE
Neuroscience; 1997 Nov; 81(2):399-404. PubMed ID: 9300430
[TBL] [Abstract][Full Text] [Related]
7. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
[TBL] [Abstract][Full Text] [Related]
8. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
[TBL] [Abstract][Full Text] [Related]
9. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
[TBL] [Abstract][Full Text] [Related]
10. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.
Schultz W; Studer A; Jonsson G; Sundström E; Mefford I
Neurosci Lett; 1985 Aug; 59(2):225-32. PubMed ID: 3877257
[TBL] [Abstract][Full Text] [Related]
11. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology.
Imai H; Nakamura T; Endo K; Narabayashi H
Brain Res; 1988 Dec; 474(2):327-32. PubMed ID: 3264746
[TBL] [Abstract][Full Text] [Related]
12. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates.
Wichmann T; Kliem MA; DeLong MR
Exp Neurol; 2001 Feb; 167(2):410-24. PubMed ID: 11161630
[TBL] [Abstract][Full Text] [Related]
13. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
Tsukahara T; Takeda M; Shimohama S; Ohara O; Hashimoto N
Neurosurgery; 1995 Oct; 37(4):733-9; discussion 739-41. PubMed ID: 8559303
[TBL] [Abstract][Full Text] [Related]
14. Alterations in multiple tyrosine hydroxylase mRNAs in the substantia nigra, locus coeruleus and adrenal gland of MPTP-treated parkinsonian monkeys.
Ohye T; Ichinose H; Ogawa M; Yoshida M; Nagatsu T
Neurodegeneration; 1995 Mar; 4(1):81-5. PubMed ID: 7600187
[TBL] [Abstract][Full Text] [Related]
15. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.
Schneider JS; Yuwiler A; Markham CH
Brain Res; 1987 May; 411(1):144-50. PubMed ID: 2886180
[TBL] [Abstract][Full Text] [Related]
16. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Alexander GM; Schwartzman RJ; Brainard L; Gordon SW; Grothusen JR
Brain Res; 1992 Aug; 588(2):261-9. PubMed ID: 1356591
[TBL] [Abstract][Full Text] [Related]
17. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Yoshimura N; Mizuta E; Kuno S; Sasa M; Yoshida O
Neuropharmacology; 1993 Apr; 32(4):315-21. PubMed ID: 8098860
[TBL] [Abstract][Full Text] [Related]
18. Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys.
Schneider JS; Sun ZQ; Roeltgen DP
Brain Res; 1994 Nov; 663(1):140-4. PubMed ID: 7850462
[TBL] [Abstract][Full Text] [Related]
19. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
[TBL] [Abstract][Full Text] [Related]
20. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
